MEDI 559

Drug Profile

MEDI 559

Alternative Names: MEDI-559; RSV vaccine (MEDI-559)

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer MedImmune
  • Class Respiratory syncytial virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 31 Mar 2015 Discontinued - Phase-I/II for Respiratory syncytial virus infections (In infants, Prevention) in USA (Intranasal)
  • 01 Aug 2012 MedImmune completes a phase I/II trial for prevention of Respiratory syncytial virus infections in USA (NCT00767416)
  • 06 Jul 2009 MEDI 559 is still in phase I/II trials for prevention of Respiratory syncytial virus infections in healthy infants in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top